Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Servicesource International Inc (SREV), Recro Pharma Inc (REPH): Altai Capital And Broadfin Capital’s Latest Moves

According to a recent filing with the Securities and Exchange Commission, Altai Capital, run by Rishi Bajaj, Toby Symonds and Steve Tesoriere, has increased its holding of Servicesource International Inc (NASDAQ:SREV). As a result, Altai Capital now holds 11.7 million shares, up from the 8.22 million shares reported in its latest 13F filing.

Phil Frohlich is also bullish on Servicesource International Inc (NASDAQ:SREV), having increased his fund’s investment in the company by 185% during the second quarter of this year. Prescott Group Capital Management reportedly holds 3.01 million shares valued at approximately $17.4 million. George McCabe, the manager of Portolan Capital Management, also sees Servicesource International Inc (NASDAQ:SREV) as a good investment and has built a new position for his fund during the same period of time. His fund currently holds 1.07 million shares worth $6.25 million. Chuck Royce, on the other hand, has chosen to limit his fund’s exposure to the stock and has reduced his stake by 20%. Royce & Associates has reported ownership of approximately 943,900 shares valued at $5.47 million in its latest 13F filing.

Rishi Bajaj - Altai Capital

Kevin Kotler thinks Recro Pharma Inc (NASDAQ:REPH) stock is poised to go higher and has boosted his fund’s stake in the company. According to a recent filing with the Securities and Exchange commission, Kotler has added 500,000 shares to his fund’s previous position, taking it to 1.17 million shares. As a result, Broadfin Capital now has control over 15.2% of the company’s common stock.

From the hedge funds we track, Broadfin Capital is the only one invested in Recro Pharma Inc (NASDAQ:REPH). The company engages in the development of non-opioid therapeutics for the treatment of pain. On September 4th, Recro Pharma Inc (NASDAQ:REPH) announced an update to its research strategy for Dex-IN (intranasal dexmedetomidine). Based on prior observations, a revised approach to the study is “the best path forward”, according to Gerri Henwood, Recro Pharma’s President and Chief Executive Officer.

Warren Buffett and BillionairesFree Report: Warren Buffett and 12 Billionaires Are Crazy About These 7 Stocks

Let Warren Buffett, David Einhorn, George Soros, and David Tepper WORK FOR YOU. If you want to beat the low cost index funds by an average of 6 percentage points per year look no further than Warren Buffett’s stock picks. That’s the margin Buffett’s stock picks outperformed the market since 2008. In this free report, Insider Monkey’s market beating research team identified 7 stocks Warren Buffett and 12 other billionaires are crazy about. CLICK HERE NOW for all the details.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!